UniProt Q07817
Bcl-2-like protein 1 (Q07817)
Bcl-2-like protein 1 (UniProt Q07817): 186 experimental structures and 1 predicted model on GenesisL1, 23 ligands bound, 33 pockets. Binding sites, druggability and experiment against prediction (TM-score) in GL1X.
- UniProt
- Q07817
- Protein
- Bcl-2-like protein 1
- Experimental structures
- 186
- Predicted models
- 1
- Ligands
- 23
- Pockets
- 33 · 6 records with a druggable one
Structures
187 records of Q07817 in the MolNFT archive: 186 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1BXL | Structure of BCL-XL/BAK peptide complex, NMR, minimized average structure | solution nmr | A | — | — |
| 1BXL | Structure of BCL-XL/BAK peptide complex, NMR, minimized average structure | solution nmr | A | — | — |
| 1G5J | Complex of BCL-xl with peptide from bad | solution nmr | A | — | — |
| 1G5J | Complex of BCL-xl with peptide from bad | solution nmr | A | — | — |
| 1G5M | Human BCL-2, isoform 1 | solution nmr | A | — | — |
| 1G5M | Human BCL-2, isoform 1 | solution nmr | A | — | — |
| 1GJH | Human BCL-2, isoform 2 | solution nmr | A | — | — |
| 1GJH | Human BCL-2, isoform 2 | solution nmr | A | — | — |
| 1LXL | NMR structure of BCL-xl, an inhibitor of programmed cell death, minimized average structure | solution nmr | A | — | — |
| 1LXL | NMR structure of BCL-xl, an inhibitor of programmed cell death, minimized average structure | solution nmr | A | — | — |
| 1MAZ | X-ray structure of BCL-xl, an inhibitor of programmed cell death | x-ray diffraction | A | — | — |
| 1MAZ | X-ray structure of BCL-xl, an inhibitor of programmed cell death | x-ray diffraction | A | — | — |
| 1R2D | Structure of Human Bcl-XL at 1.95 Angstroms | x-ray diffraction | A | — | — |
| 1R2D | Structure of human BCL-xl at 1.95 ångströms | x-ray diffraction | A | — | — |
| 1R2E | Human Bcl-XL containing a Glu to Leu mutation at position 92 | x-ray diffraction | A | — | — |
| 1R2E | Human BCL-xl containing a glu to leu mutation at position 92 | x-ray diffraction | A | — | — |
| 1R2G | Human Bcl-XL containing a Phe to Trp mutation at position 97 | x-ray diffraction | A | — | — |
| 1R2G | Human BCL-xl containing a phe to TRP mutation at position 97 | x-ray diffraction | A | — | — |
| 1R2H | Human Bcl-XL containing an Ala to Leu mutation at position 142 | x-ray diffraction | A | — | — |
| 1R2H | Human BCL-xl containing an ala to leu mutation at position 142 | x-ray diffraction | A | — | — |
| 1R2I | Human Bcl-XL containing a Phe to Leu mutation at position 146 | x-ray diffraction | A | — | — |
| 1R2I | Human BCL-xl containing a phe to leu mutation at position 146 | x-ray diffraction | A | — | — |
| 1YSG | Solution Structure of the Anti-apoptotic Protein Bcl-xL in Complex with "SAR by NMR" Ligands | solution nmr | A | — | — |
| 1YSG | Solution structure of the anti-apoptotic protein BCL-xl in complex with "sar by NMR" ligands | solution nmr | A | — | — |
| 1YSI | Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 1YSI | Solution structure of the anti-apoptotic protein BCL-xl in complex with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 1YSN | Solution structure of the anti-apoptotic protein Bcl-xL complexed with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 1YSN | Solution structure of the anti-apoptotic protein BCL-xl complexed with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 2B48 | Bcl-XL 3D Domain Swapped Dimer | x-ray diffraction | A | — | — |
| 2B48 | BCL-xl 3D domain swapped dimer | x-ray diffraction | A | — | — |
| 2LP8 | SOLUTION STRUCTURE OF AN APOPTOSIS ACTIVATING PHOTOSWITCHABLE BAK PEPTIDE BOUND to BCL-XL | solution nmr | A | — | — |
| 2LP8 | Solution structure of an apoptosis activating photoswitchable bak peptide bound to BCL-xl | solution nmr | A | — | — |
| 2LPC | NMR STRUCTURE of Bcl-XL | solution nmr | A | — | — |
| 2LPC | NMR structure of BCL-xl | solution nmr | A | — | — |
| 2M03 | Solution structure of BCL-xL determined with selective isotope labelling of I,L,V sidechains | solution nmr | A | — | — |
| 2M03 | Solution structure of BCL-xl determined with selective isotope labelling of I,L,V sidechains | solution nmr | A | — | — |
| 2M04 | Solution structure of BCL-xL in complex with PUMA BH3 peptide | solution nmr | A | — | — |
| 2M04 | Solution structure of BCL-xl in complex with puma BH3 peptide | solution nmr | A | — | — |
| 2ME8 | Solution Structure of BCL-xL in its p53-bound conformation determined with selective isotope… | solution nmr | A | — | — |
| 2ME8 | Solution structure of BCL-xl in its P53-bound conformation determined with selective isotope… | solution nmr | A | — | — |
| 2ME9 | Solution structure of BCL-xL containing the alpha1-alpha2 disordered loop determined with selective… | solution nmr | A | — | — |
| 2ME9 | Solution structure of BCL-xl containing the ALPHA1-ALPHA2 disordered loop determined with selective… | solution nmr | A | — | — |
| 2MEJ | Solution Structure of the Complex Between BCL-xL and the p53 Core Domain determined with PRE… | solution nmr | A | — | — |
| 2MEJ | Solution structure of the complex between BCL-xl and the P53 core domain determined with pre… | solution nmr | A | — | — |
| 2O1Y | Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 2O1Y | Solution structure of the anti-apoptotic protein BCL-xl in complex with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 2O21 | Solution structure of the anti-apoptotic protein Bcl-2 in complex with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 2O21 | Solution structure of the anti-apoptotic protein BCL-2 in complex with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 2O22 | Solution structure of the anti-apoptotic protein Bcl-2 in complex with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 2O22 | Solution structure of the anti-apoptotic protein BCL-2 in complex with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 2O2M | Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 2O2M | Solution structure of the anti-apoptotic protein BCL-xl in complex with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 2O2N | Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 2O2N | Solution structure of the anti-apoptotic protein BCL-xl in complex with an acyl-sulfonamide-based… | solution nmr | A | — | — |
| 2P1L | Structure of the Bcl-XL:Beclin 1 complex | x-ray diffraction | A, C, E, G | — | — |
| 2P1L | Structure of the BCL-XL:BECLIN 1 complex | x-ray diffraction | A, C, E, G | — | — |
| 2PON | Solution structure of the Bcl-xL/Beclin-1 complex | solution nmr | B | — | — |
| 2PON | Solution structure of the BCL-XL/BECLIN-1 complex | solution nmr | B | — | — |
| 2YJ1 | Puma BH3 foldamer in complex with Bcl-xL | x-ray diffraction | A, C | — | — |
| 2YJ1 | Puma BH3 foldamer in complex with BCL-xl | x-ray diffraction | A, C | — | — |
127 records more on the page itself.
Ligands
- SO4 · Sulfate ion · in 9 records
- LBM · 4-{4-[(4'-chloro-5,5-dimethyl[3,4,5,6-tetrahydro[1,1'-biphenyl]]-2-yl)methyl]piperazin-1-yl}-N-[(3-nitro-4-{[(oxan-4-yl)methyl]amino}phenyl)sulfonyl]-2-[(1H-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide · in 6 records
- CL · Chloride ion · in 3 records
- F3Q · ~{N}-(4-hydroxyphenyl)-3-[6-[[(3~{S})-3-(morpholin-4-ylmethyl)-3,4-dihydro-1~{H}-isoquinolin-2-yl]carbonyl]-1,3-benzodioxol-5-yl]-~{N}-phenyl-5,6,7, 8-tetrahydroindolizine-1-carboxamide · in 2 records
- J1H · [(3~{R})-3-[[4-[[4-[4-[[2-(4-chlorophenyl) phenyl]methyl]piperazin-1-yl]phenyl]carbonylsulfamoyl]-2-nitro-phenyl]amino]-4-phenylsulfanyl-butyl]-(2-hydroxy-2-oxoethyl)-dimethyl-azanium · in 2 records
- V9S · 6-[(8E)-8-{2-[4-(benzylcarbamoyl)-1,3-thiazol-2-yl]hydrazinylidene}-5,6,7,8-tetrahydronaphthalen-2-yl]-3-(2-phenylethoxy)pyridine-2-carboxylic acid · in 2 records
- XOY · (R)-3-(Benzylthio)-2-(3-(2-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-6-carbonyl)-3-(4-methylbenzyl)ureido)propanoic acid · in 2 records
- 1XJ · 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]benzamide · in 1 record
- BR · Bromide ion · in 1 record
- J1Q · 1-[2-[[(3~{S})-3-(aminomethyl)-3,4-dihydro-1~{H}-isoquinolin-2-yl]carbonyl]phenyl]-~{N},~{N}-dibutyl-5-methyl-pyrazole-3-carboxamide · in 1 record
- J1T · 4-[4-[(1~{R})-1-(6-methoxy-1,3-benzodioxol-5-yl)-2-pyrrolidin-1-yl-ethyl]phenyl]-~{N}-[4-[[(2~{R})-4-morpholin-4-yl-1-phenylsulfanyl-butan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonyl-benzamide · in 1 record
- JFF · (2R)-3-[2-(aminomethyl)-3-azanyl-1-[4-[2-(2-chloranylethanoylamino)ethylcarbamoyl]phenyl]prop-1-enyl]sulfanyl-2-(carboxyamino)propanoic acid · in 1 record
- KBH · 4-(4-fluorophenyl)-3-fluorosulfonyl-benzoic acid · in 1 record
- QHJ · (R)-2-(3-(2-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)-1, 2,3,4-tetrahydroisoquinoline-6-carbonyl)-3-(4-methylbenzyl)ureido)-3-((cyclohexylmethyl)sulfonyl) propanoic acid · in 1 record
- QHP · (R)-2-(3-([1,1'-biphenyl]-4-carbonyl)-3-(4-methylbenzyl)ureido)-3-(((3R,5R,7R)-adamantan-1-ylmethyl)sulfonyl)propanoic acid · in 1 record
- QHS · (R)-2-(3-([1,1'-biphenyl]-4-carbonyl)-3-(4-methylbenzyl)ureido)-3-((cyclohexylmethyl)sulfonyl) propanoic acid · in 1 record
- QHV · (R)-3-(benzylthio)-2-(3-(4-chloro-[1,1':2',1'':3'', 1'''-quaterphenyl]-4'''-carbonyl)-3-(4-methylbenzyl) ureido)propanoic acid · in 1 record
- RQ7 · 6-{8-[(1,3-benzothiazol-2-yl)carbamoyl]-3,4-dihydroisoquinolin-2(1H)-yl}-3-{1-[(pyridin-4-yl) methyl]-1H-pyrazol-4-yl}pyridine-2-carboxylic acid · in 1 record
- ULL · propan-2-yl {4-[(5S)-1-(4-bromobenzoyl)-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl]phenyl}carbamate · in 1 record
- XOU · (2R)-3-(benzylsulfanyl)-2-({[(4-methylphenyl)methyl] [(4 phenylphenyl)carbonyl] carbamoyl}amino) propanoic acid · in 1 record
- XZM · N-(1,3-benzothiazol-2-yl)-2-(4-{[(4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl) sulfonyl]carbamoyl}-1,3-thiazol-2-yl)-1,2,3,4-tetrahydroisoquinoline-8-carboxamide · in 1 record
- YF8 · N-[8-(4-{[(1R,3R,4S)-4-(4-chlorophenyl)-1-methyl-3-{[4-(4-{[4-{[(2R)-4-(morpholin-4-yl)-1-(phenylsulfanyl)butan-2-yl]amino}-3-(trifluoromethanesulfonyl)benzene-1-sulfonyl]carbamoyl}phenyl)piperazin-1-yl]methyl}cyclohexyl]methyl}piperazin-1-yl)-8-oxooctanoyl]-3-methyl-L-valyl-(4R)-4-hydroxy-N-{(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl}-L-prolinamide · in 1 record
- ZN · Zinc ion · in 1 record
Experiment against prediction
- 3QKD chain B against the predicted model Q07817: TM-score 0.99, RMSD 0.56 Å
- 3QKD chain B against the predicted model Q07817: TM-score 0.99, RMSD 0.56 Å
- 2YXJ chain B against the predicted model Q07817: TM-score 0.99, RMSD 0.59 Å
- 2YXJ chain B against the predicted model Q07817: TM-score 0.99, RMSD 0.59 Å
- 2YXJ chain A against the predicted model Q07817: TM-score 0.98, RMSD 0.56 Å
- 2YXJ chain A against the predicted model Q07817: TM-score 0.98, RMSD 0.56 Å
- 3QKD chain A against the predicted model Q07817: TM-score 0.98, RMSD 0.59 Å
- 3QKD chain A against the predicted model Q07817: TM-score 0.98, RMSD 0.59 Å
- 6QG8 chain A against the predicted model P10415: TM-score 0.98, RMSD 0.64 Å
- 6QG8 chain A against the predicted model P10415: TM-score 0.98, RMSD 0.64 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.